Company profile: Vir Biotechnology
1.1 - Company Overview
Company description
- Provider of immunology-based products to treat and prevent infectious diseases and other serious conditions, including Phase 2 tobevibart + elebsiran for chronic hepatitis delta and elebsiran + PEG-IFN-α for chronic hepatitis B; Phase 1 VIR-1388 for HIV prevention; and preclinical candidates VIR-8190 (RSV & hMPV), VIR-2981 (influenza A/B), and VIR-1949 (pre-cancerous HPV lesions).
Products and services
- Elebsiran + PEG-IFN-α (Chronic Hepatitis B): A Phase 2 clinical-stage regimen for Chronic Hepatitis B combining siRNA with peginterferon alpha, engineered by Vir Biotechnology and evaluated as a combination therapy in ongoing trials
- Tobevibart + elebsiran (Chronic Hepatitis Delta): A Phase 2 clinical-stage combination treatment for Chronic Hepatitis Delta utilizing a monoclonal antibody with siRNA, architected by Vir Biotechnology and evaluated in trials for HDV
- VIR-1388 (HIV Prevention): A Phase 1 investigational T cell vaccine candidate for HIV prevention, developed by Vir Biotechnology and undergoing clinical testing to assess preventive potential
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Vir Biotechnology
Calidi Biotherapeutics
HQ: United States
Website
- Description: Provider of clinical-stage cancer immunotherapies based on stem cell-delivered oncolytic viruses. Programs include NeuroNova (neural stem cells + oncolytic adenovirus) for glioblastoma; SuperNova (adipose-derived mesenchymal stem cells + oncolytic vaccinia) for advanced solid tumors; RTNova, a systemic enveloped oncolytic virotherapy; CLD-101 in Phase 1 for recurrent high-grade glioma; and CLD-201, a cell-based virotherapy planned for Phase 1.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Calidi Biotherapeutics company profile →
Scancell
HQ: United Kingdom
Website
- Description: Provider of immunotherapy platforms and therapeutic vaccines for cancer and infectious diseases, including ImmunoBody and Moditope for cancer vaccines, GlyMab for glycan-targeting monoclonal antibodies, AvidiMab to enhance antibody potency and tumor specificity, and melanoma vaccines SCIB1 and iSCIB1+.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Scancell company profile →
AnaptysBio
HQ: United States
Website
- Description: Provider of antibody therapeutics developed via somatic hypermutation, including Imsidolimab (IgG4 anti-IL-36 receptor) for generalized pustular psoriasis; Rosnilimab (PD-1 agonist) for rheumatoid arthritis and ulcerative colitis; ANB032 (BTLA agonist) for atopic dermatitis; ANB033 (anti-CD122 antagonist) for autoimmune and inflammatory diseases; and ANB101 (BDCA2 modulator) targeting plasmacytoid dendritic cells to inhibit interferon secretion.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AnaptysBio company profile →
Calypso Biotech
HQ: Switzerland
Website
- Description: Provider of biopharmaceutical research and development focused on therapeutics for autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Calypso Biotech company profile →
Immunovant
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical offerings focused on enabling normal lives for patients with autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunovant company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Vir Biotechnology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vir Biotechnology
2.2 - Growth funds investing in similar companies to Vir Biotechnology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Vir Biotechnology
4.2 - Public trading comparable groups for Vir Biotechnology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →